Shan Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shan Lin has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Wanmei He
Department of Medical Intensive Care Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China
12 shared publications- Qingyuan Zhan
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China
9 shared publications - Mian Zeng
Department of Medical Intensive Care Unit, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
7 shared publications Xin Dang
6 shared publicationsShanhui Ge
5 shared publications- Wei Guan
Department of Respiratory Medicine, The Central Hospital of Baoan, Shenzhen, Guangdong Province, China
4 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1792149
Association between baseline neutrophil-to-lymphocyte ratio and short-term hearing recovery after glucocorticoid therapy in idiopathic sudden sensorineural hearing loss
Objective: This study aimed to evaluate the predictive value of the neutrophil-to-lymphocyte ratio (NLR) for day-7 hearing recovery following oral glucocorticoid therapy in patients with idiopathic sudden sensorineural hearing loss (ISSNHL). Methods: We retrospectively reviewed the medical records of 214 patients with unilateral ISSNHL who were admitted to the Department of Otolaryngology–Head and Neck Surgery between 2022 and 2025. Multivariable logistic regression was used to assess the association between baseline NLR and day-7 recovery status (recovered vs. non-recovered), and E-values were calculated to evaluate the potential impact of unmeasured confounders. Stratified analyses and interaction tests were performed to examine potential effect modifications across predefined subgroups. Receiver operating characteristic (ROC) curve analysis was conducted to assess predictive performance, and the optimal NLR threshold was determined using the Youden index. To address potential overfitting and improve reproducibility, internal validation and calibration of the NLR-only model were performed using bootstrap resampling, including the optimism-corrected AUC, Brier score, calibration-in-the-large, and calibration slope. Results: A higher NLR was significantly associated with a lower likelihood of day-7 hearing recovery. In the fully adjusted model, the odds ratio (OR) for NLR was 0.40 [95% confidence interval (CI), 0.30–0.53]. The E-value was 2.54 (upper limit of the 95% CI, 2.09), supporting the robustness to unmeasured confounding factors. This association was generally consistent across subgroup analyses. ROC analysis showed strong predictive accuracy, with an apparent AUC of 0.90 (95% CI, 0.85–0.95). The optimal NLR cut-off was 4.59, with a specificity of 97.66% and a sensitivity of 80.23%. Bootstrap internal validation demonstrated minimal overfitting (optimism-corrected AUC 0.90) and satisfactory calibration (optimism-corrected calibration-in-the-large = 0.0039; calibration slope = 1.0032). Conclusion: Baseline NLR is a simple and readily available biomarker that predicts day-7 hearing recovery following oral glucocorticoid therapy in patients with ISSNHL. An elevated NLR is associated with a lower probability of recovery, supporting its potential utility for early risk stratification; nevertheless, external validation in independent cohorts is warranted.
- 2 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1792149
Open AccessAssociation between baseline neutrophil-to-lymphocyte ratio and short-term hearing recovery after glucocorticoid therapy in idiopathic sudden sensorineural hearing loss
Objective: This study aimed to evaluate the predictive value of the neutrophil-to-lymphocyte ratio (NLR) for day-7 hearing recovery following oral glucocorticoid therapy in patients with idiopathic sudden sensorineural hearing loss (ISSNHL). Methods: We retrospectively reviewed the medical records of 214 patients with unilateral ISSNHL who were admitted to the Department of Otolaryngology–Head and Neck Surgery between 2022 and 2025. Multivariable logistic regression was used to assess the association between baseline NLR and day-7 recovery status (recovered vs. non-recovered), and E-values were calculated to evaluate the potential impact of unmeasured confounders. Stratified analyses and interaction tests were performed to examine potential effect modifications across predefined subgroups. Receiver operating characteristic (ROC) curve analysis was conducted to assess predictive performance, and the optimal NLR threshold was determined using the Youden index. To address potential overfitting and improve reproducibility, internal validation and calibration of the NLR-only model were performed using bootstrap resampling, including the optimism-corrected AUC, Brier score, calibration-in-the-large, and calibration slope. Results: A higher NLR was significantly associated with a lower likelihood of day-7 hearing recovery. In the fully adjusted model, the odds ratio (OR) for NLR was 0.40 [95% confidence interval (CI), 0.30–0.53]. The E-value was 2.54 (upper limit of the 95% CI, 2.09), supporting the robustness to unmeasured confounding factors. This association was generally consistent across subgroup analyses. ROC analysis showed strong predictive accuracy, with an apparent AUC of 0.90 (95% CI, 0.85–0.95). The optimal NLR cut-off was 4.59, with a specificity of 97.66% and a sensitivity of 80.23%. Bootstrap internal validation demonstrated minimal overfitting (optimism-corrected AUC 0.90) and satisfactory calibration (optimism-corrected calibration-in-the-large = 0.0039; calibration slope = 1.0032). Conclusion: Baseline NLR is a simple and readily available biomarker that predicts day-7 hearing recovery following oral glucocorticoid therapy in patients with ISSNHL. An elevated NLR is associated with a lower probability of recovery, supporting its potential utility for early risk stratification; nevertheless, external validation in independent cohorts is warranted.
- Open Access
Causal and shared genetic insights into severe COVID-19 and idiopathic pulmonary fibrosis
- Open Access
Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis
Background: Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains underrecognized. The objective of this study was to investigate whether commonly prescribed antidiabetic medications, including glucagon‐like peptide‐1 receptor agonists, dipeptidyl peptidase‐4 inhibitors, metformin, and sodium‐glucose cotransporter‐2 inhibitors, are associated with an increased reporting of erectile dysfunction in real‐world clinical practice. Methods: This retrospective pharmacovigilance study was conducted using the FDA Adverse Event Reporting System. A disproportionality analysis was performed to evaluate the reporting frequency of erectile dysfunction associated with commonly prescribed antidiabetic medications. The reporting odds ratio served as the primary metric for evaluating disproportionality in adverse event reporting. In addition, time‐to‐onset and Weibull shape parameter analyses were performed to assess temporal trends in adverse event occurrence. Results: We identified 49 semaglutide‐, 54 sitagliptin‐, and 42 dapagliflozin‐associated erectile dysfunction reports. All three drugs demonstrated significant disproportionality signals: semaglutide (reporting odds ratio: 1.53, 95% confidence interval: 1.16–2.03; information component 025 = 0.19), sitagliptin (reporting odds ratio: 1.52, 95% confidence interval: 1.16–1.98; information component 025 = 0.20), and dapagliflozin (reporting odds ratio: 1.51, 95% confidence interval: 1.11–2.04; information component 025 = 0.13). Time‐to‐onset analysis indicated a random failure‐type distribution for all three drugs (semaglutide, sitagliptin, and dapagliflozin), suggesting that the occurrence of erectile dysfunction appears relatively random over the course of treatment rather than concentrated shortly after initiation and underscoring the need for continuous monitoring throughout therapy. Other agents in the same drug classes, including dulaglutide, linagliptin, and metformin, did not show significant signals. Conclusions: This FDA Adverse Event Reporting System‐based pharmacovigilance analysis identified potential safety signals linking erectile dysfunction to semaglutide, sitagliptin, and dapagliflozin. These findings do not establish causality and should be regarded as preliminary and hypothesis‐generating. Further mechanistic and prospective clinical studies are needed to determine whether these signals reflect true drug‐related risks. Clinicians should be aware that erectile dysfunction has been reported in some users of these agents and may consider incorporating sexual health into routine discussions and shared decision‐making with male patients.
Open AccessSexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis
Background: Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains underrecognized. The objective of this study was to investigate whether commonly prescribed antidiabetic medications, including glucagon‐like peptide‐1 receptor agonists, dipeptidyl peptidase‐4 inhibitors, metformin, and sodium‐glucose cotransporter‐2 inhibitors, are associated with an increased reporting of erectile dysfunction in real‐world clinical practice. Methods: This retrospective pharmacovigilance study was conducted using the FDA Adverse Event Reporting System. A disproportionality analysis was performed to evaluate the reporting frequency of erectile dysfunction associated with commonly prescribed antidiabetic medications. The reporting odds ratio served as the primary metric for evaluating disproportionality in adverse event reporting. In addition, time‐to‐onset and Weibull shape parameter analyses were performed to assess temporal trends in adverse event occurrence. Results: We identified 49 semaglutide‐, 54 sitagliptin‐, and 42 dapagliflozin‐associated erectile dysfunction reports. All three drugs demonstrated significant disproportionality signals: semaglutide (reporting odds ratio: 1.53, 95% confidence interval: 1.16–2.03; information component 025 = 0.19), sitagliptin (reporting odds ratio: 1.52, 95% confidence interval: 1.16–1.98; information component 025 = 0.20), and dapagliflozin (reporting odds ratio: 1.51, 95% confidence interval: 1.11–2.04; information component 025 = 0.13). Time‐to‐onset analysis indicated a random failure‐type distribution for all three drugs (semaglutide, sitagliptin, and dapagliflozin), suggesting that the occurrence of erectile dysfunction appears relatively random over the course of treatment rather than concentrated shortly after initiation and underscoring the need for continuous monitoring throughout therapy. Other agents in the same drug classes, including dulaglutide, linagliptin, and metformin, did not show significant signals. Conclusions: This FDA Adverse Event Reporting System‐based pharmacovigilance analysis identified potential safety signals linking erectile dysfunction to semaglutide, sitagliptin, and dapagliflozin. These findings do not establish causality and should be regarded as preliminary and hypothesis‐generating. Further mechanistic and prospective clinical studies are needed to determine whether these signals reflect true drug‐related risks. Clinicians should be aware that erectile dysfunction has been reported in some users of these agents and may consider incorporating sexual health into routine discussions and shared decision‐making with male patients.
- Open Access
- 15 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (12)
Identification of novel therapeutic targets for diabetic neuropathy through integrated proteomics and transcriptomics approaches
BACKGROUND Diabetic neuropathy (DN) is a progressive disorder with limited effective treatment options. AIM To identify potential therapeutic targets for DN by integrating plasma proteomic and transcriptomic data. METHODS A comprehensive analytical framework was developed to identify multi-omics biomarkers of DN. Protein-protein interaction network and Gene Ontology analyses were performed to explore the biological functions of biomarkers. Tier 1 target proteins were further analyzed. Candidate drug prediction and molecular docking studies were conducted to identify potential treatments while assessing the side effects of key target proteins. The mediation of immune cells in the association between proteins and DN was examined through two-step network Mendelian randomization (MR) analysis. RESULTS Nine DN-associated proteins were identified by analyzing protein quantitative trait loci from extensive genome-wide association study data. BTN3A1 and MICB were confirmed using MR, summary data-based MR, and colocalization analyses. Of the nine, HSPA1B, PSMB9, BTN3A1, SCGN, NOTUM, and MICB showed negative associations with DN, whereas WARS, BRD2, and CSNK2B were positive. Gene Ontology analysis indicated enrichment in inflammatory response and neuronal injury pathways. BTN3A1 and MICB were identified as Tier 1 targets. Drug prediction and molecular docking analyses indicated cyclosporin A as a potential therapeutic candidate. Two-step network MR analysis showed that MICB mediated DN through human leukocyte antigen-DR++ monocytes. These integrated findings point to an immune-mediated mechanism with translational potential and nominate BTN3A1 and MICB for focused functional validation. CONCLUSION Our integrated multi-omics approach identified two promising therapeutic targets for DN, laying the groundwork for new treatment strategies and enhancing our understanding of MICB’s role in DN.
- 15 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (12)
Open AccessIdentification of novel therapeutic targets for diabetic neuropathy through integrated proteomics and transcriptomics approaches
BACKGROUND Diabetic neuropathy (DN) is a progressive disorder with limited effective treatment options. AIM To identify potential therapeutic targets for DN by integrating plasma proteomic and transcriptomic data. METHODS A comprehensive analytical framework was developed to identify multi-omics biomarkers of DN. Protein-protein interaction network and Gene Ontology analyses were performed to explore the biological functions of biomarkers. Tier 1 target proteins were further analyzed. Candidate drug prediction and molecular docking studies were conducted to identify potential treatments while assessing the side effects of key target proteins. The mediation of immune cells in the association between proteins and DN was examined through two-step network Mendelian randomization (MR) analysis. RESULTS Nine DN-associated proteins were identified by analyzing protein quantitative trait loci from extensive genome-wide association study data. BTN3A1 and MICB were confirmed using MR, summary data-based MR, and colocalization analyses. Of the nine, HSPA1B, PSMB9, BTN3A1, SCGN, NOTUM, and MICB showed negative associations with DN, whereas WARS, BRD2, and CSNK2B were positive. Gene Ontology analysis indicated enrichment in inflammatory response and neuronal injury pathways. BTN3A1 and MICB were identified as Tier 1 targets. Drug prediction and molecular docking analyses indicated cyclosporin A as a potential therapeutic candidate. Two-step network MR analysis showed that MICB mediated DN through human leukocyte antigen-DR++ monocytes. These integrated findings point to an immune-mediated mechanism with translational potential and nominate BTN3A1 and MICB for focused functional validation. CONCLUSION Our integrated multi-omics approach identified two promising therapeutic targets for DN, laying the groundwork for new treatment strategies and enhancing our understanding of MICB’s role in DN.
- Open Access
- 8 October 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1652216
Global, regional, and national disease burden of pneumoconiosis, chronic obstructive pulmonary disease, tracheal-bronchus-and-lung cancer, and asthma attributable to occupational risks, 1990–2021: a systematic analysis for the global burden of disease study 2021
Background: Occupational risks contribute substantially to the global burden of pneumoconiosis, chronic obstructive pulmonary disease (COPD), tracheal-bronchus-and-lung (TBL) cancer, and asthma; however, comprehensive, up-to-date global, regional, and national estimates remain limited.Methods: Data from the Global Burden of Disease Study (GBD) 2021 were analyzed to quantify the burden of these diseases attributable to occupational exposure across 204 countries between 1990 and 2021, stratified by sex, age, socio-demographic index (SDI), and geographic region.Results: In 2021, occupational risks led to 30,546 deaths due to pneumoconiosis, 285,628 deaths due to COPD, 585,451 deaths due to TBL (the highest among the four diseases), and 18,315 deaths due to asthma, with disability-adjusted life years (DALYs) of 1.8, 6.1, 12.6, and 0.4 million, respectively. Male patients exhibited higher burdens of all diseases, reflecting greater exposure to male-dominated industries. Geographically, middle SDI regions had the highest absolute cases for pneumoconiosis and COPD, high-SDI regions for TBL cancer, and low-middle SDI regions for asthma. While age-standardized rates declined for most outcomes over time, the absolute burdens increased owing to population growth and aging, with demographic factors driving up to 80% of the increase in total cases. Health inequities persisted, with lower SDI regions bearing a disproportionate burden, despite modest improvements in absolute inequalities.Conclusion: These findings highlight the need for strengthened occupational health regulations, targeted interventions in high-risk regions, and policies addressing population dynamics to mitigate the impact of workplace exposure on respiratory health.
- 8 October 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1652216
Open AccessGlobal, regional, and national disease burden of pneumoconiosis, chronic obstructive pulmonary disease, tracheal-bronchus-and-lung cancer, and asthma attributable to occupational risks, 1990–2021: a systematic analysis for the global burden of disease study 2021
Background: Occupational risks contribute substantially to the global burden of pneumoconiosis, chronic obstructive pulmonary disease (COPD), tracheal-bronchus-and-lung (TBL) cancer, and asthma; however, comprehensive, up-to-date global, regional, and national estimates remain limited.Methods: Data from the Global Burden of Disease Study (GBD) 2021 were analyzed to quantify the burden of these diseases attributable to occupational exposure across 204 countries between 1990 and 2021, stratified by sex, age, socio-demographic index (SDI), and geographic region.Results: In 2021, occupational risks led to 30,546 deaths due to pneumoconiosis, 285,628 deaths due to COPD, 585,451 deaths due to TBL (the highest among the four diseases), and 18,315 deaths due to asthma, with disability-adjusted life years (DALYs) of 1.8, 6.1, 12.6, and 0.4 million, respectively. Male patients exhibited higher burdens of all diseases, reflecting greater exposure to male-dominated industries. Geographically, middle SDI regions had the highest absolute cases for pneumoconiosis and COPD, high-SDI regions for TBL cancer, and low-middle SDI regions for asthma. While age-standardized rates declined for most outcomes over time, the absolute burdens increased owing to population growth and aging, with demographic factors driving up to 80% of the increase in total cases. Health inequities persisted, with lower SDI regions bearing a disproportionate burden, despite modest improvements in absolute inequalities.Conclusion: These findings highlight the need for strengthened occupational health regulations, targeted interventions in high-risk regions, and policies addressing population dynamics to mitigate the impact of workplace exposure on respiratory health.
- Open Access
- 4 September 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1616294
Early administration of magnesium sulfate and its impact on clinical outcomes in ICU-admitted patients with COPD: a retrospective cohort study
Background: Magnesium sulfate is commonly utilized in critical care due to its vasodilatory, bronchodilatory, and neuroprotective properties. However, its impact on mortality outcomes in patients with chronic obstructive pulmonary disease (COPD) requiring intensive care remains inadequately defined.Methods: A retrospective cohort study was conducted on patients with COPD who were admitted to the ICU at Beth Israel Deaconess Medical Center in Boston from 2008 to 2019. Early administration of magnesium sulfate was considered for intravenous administration within 48 h of ICU admission. Propensity-score-based methods, such as inverse probability weighting, were employed to evaluate the correlation between early use of magnesium sulfate and 28-day mortality.Results: A total of 3,651 ICU admissions for COPD were included, of which 1,148 (31.4%) patients received magnesium sulfate within the first 48 h. Administering magnesium sulfate early was linked to a reduced 28-day mortality rate (hazard ratio 0.76, 95% confidence interval 0.60–0.95), with consistent results across predefined subgroups. This correlation remained consistent regardless of baseline serum magnesium levels and did not increase the risk of acute kidney injury (AKI). The calculated E-value of 1.96 indicates that significant unmeasured confounding factors would be necessary to fully account for the observed relationship.Conclusion: In this single-center retrospective cohort, early magnesium sulfate administration in critically ill patients with COPD was associated with lower 28-day mortality without an observed increase in AKI risk. These results advocate for prospective multicenter studies to validate these connections, investigate optimal dosing approaches, and pinpoint the patient subgroups most likely to benefit from this intervention.
- 4 September 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1616294
Open AccessEarly administration of magnesium sulfate and its impact on clinical outcomes in ICU-admitted patients with COPD: a retrospective cohort study
Background: Magnesium sulfate is commonly utilized in critical care due to its vasodilatory, bronchodilatory, and neuroprotective properties. However, its impact on mortality outcomes in patients with chronic obstructive pulmonary disease (COPD) requiring intensive care remains inadequately defined.Methods: A retrospective cohort study was conducted on patients with COPD who were admitted to the ICU at Beth Israel Deaconess Medical Center in Boston from 2008 to 2019. Early administration of magnesium sulfate was considered for intravenous administration within 48 h of ICU admission. Propensity-score-based methods, such as inverse probability weighting, were employed to evaluate the correlation between early use of magnesium sulfate and 28-day mortality.Results: A total of 3,651 ICU admissions for COPD were included, of which 1,148 (31.4%) patients received magnesium sulfate within the first 48 h. Administering magnesium sulfate early was linked to a reduced 28-day mortality rate (hazard ratio 0.76, 95% confidence interval 0.60–0.95), with consistent results across predefined subgroups. This correlation remained consistent regardless of baseline serum magnesium levels and did not increase the risk of acute kidney injury (AKI). The calculated E-value of 1.96 indicates that significant unmeasured confounding factors would be necessary to fully account for the observed relationship.Conclusion: In this single-center retrospective cohort, early magnesium sulfate administration in critically ill patients with COPD was associated with lower 28-day mortality without an observed increase in AKI risk. These results advocate for prospective multicenter studies to validate these connections, investigate optimal dosing approaches, and pinpoint the patient subgroups most likely to benefit from this intervention.
- Open Access
- 18 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (29) , e43364
Causal association between circulating cytokine levels and the risk for asthma: A bidirectional, Mendelian randomization study
Although some observational studies have linked circulating cytokine levels to asthma, their exact causal relationship(s) remain elusive. To address this knowledge gap, a Mendelian randomization (MR) study was performed to explore potential causal associations between circulating cytokine levels and asthma susceptibility using genetic instrumental variables. To investigate potential causal associations between circulating cytokines and asthma risk, a 2-sample MR analysis was performed using data from European participants from publicly available genome-wide association study summary statistics. Single nucleotide polymorphisms demonstrating significant associations with cytokine levels in previous studies were selected as instrumental genetic variables. A range of complementary MR approaches, including inverse variance weighted, weighted median, MR-Egger, weighted mode, simple mode, and MR pleiotropy residual sum and outlier (i.e., “MR-PRESSO”) methods, were implemented to comprehensively investigate causality. Genetically predicted levels of the chemokines RANTES (regulated on activation, normal T-cell expressed and secreted [CCL5]), monocyte chemoattractant protein-1 (MCP-1), and growth-regulated protein alpha (GRO-α) exhibited significant causal associations with reduced asthma susceptibility, as evidenced by odds ratios (OR) of 0.935 (95% confidence interval [CI] 0.895–0.978; P = .003), 0.951 (95% CI 0.916–0.986; P = .007), and 0.968 (95% CI 0.944–0.992; P = .011), respectively. In contrast, beta-nerve growth factor (β-NGF; OR 1.043 [95% CI 1.000–1.087], P = .048), tumor necrosis factor-alpha (TNF-α; OR 1.040 [95% CI 1.001–1.081], P = .042), and macrophage colony stimulating factor (M-CSF; OR 1.032 [95% CI 1.001–1.064], P = .043) conferred increased causal risks for the development of asthma. These causal inferences remain robust across multiple complementary MR approaches, including MR-Egger, weighted median, weighted mode, and simple mode regressions. Sensitivity analyses excluded bias from horizontal pleiotropy. This MR analysis provides initial genomic evidence supporting genetically predicted causal relationships between circulating levels of RANTES, MCP-1, GRO-α, β-NGF, TNF-α, and M-CSF and altered susceptibility to asthma. These findings highlight the potential immunopathogenic roles of these cytokines in the onset and development of asthma.
- 18 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (29) , e43364
Open AccessCausal association between circulating cytokine levels and the risk for asthma: A bidirectional, Mendelian randomization study
Although some observational studies have linked circulating cytokine levels to asthma, their exact causal relationship(s) remain elusive. To address this knowledge gap, a Mendelian randomization (MR) study was performed to explore potential causal associations between circulating cytokine levels and asthma susceptibility using genetic instrumental variables. To investigate potential causal associations between circulating cytokines and asthma risk, a 2-sample MR analysis was performed using data from European participants from publicly available genome-wide association study summary statistics. Single nucleotide polymorphisms demonstrating significant associations with cytokine levels in previous studies were selected as instrumental genetic variables. A range of complementary MR approaches, including inverse variance weighted, weighted median, MR-Egger, weighted mode, simple mode, and MR pleiotropy residual sum and outlier (i.e., “MR-PRESSO”) methods, were implemented to comprehensively investigate causality. Genetically predicted levels of the chemokines RANTES (regulated on activation, normal T-cell expressed and secreted [CCL5]), monocyte chemoattractant protein-1 (MCP-1), and growth-regulated protein alpha (GRO-α) exhibited significant causal associations with reduced asthma susceptibility, as evidenced by odds ratios (OR) of 0.935 (95% confidence interval [CI] 0.895–0.978; P = .003), 0.951 (95% CI 0.916–0.986; P = .007), and 0.968 (95% CI 0.944–0.992; P = .011), respectively. In contrast, beta-nerve growth factor (β-NGF; OR 1.043 [95% CI 1.000–1.087], P = .048), tumor necrosis factor-alpha (TNF-α; OR 1.040 [95% CI 1.001–1.081], P = .042), and macrophage colony stimulating factor (M-CSF; OR 1.032 [95% CI 1.001–1.064], P = .043) conferred increased causal risks for the development of asthma. These causal inferences remain robust across multiple complementary MR approaches, including MR-Egger, weighted median, weighted mode, and simple mode regressions. Sensitivity analyses excluded bias from horizontal pleiotropy. This MR analysis provides initial genomic evidence supporting genetically predicted causal relationships between circulating levels of RANTES, MCP-1, GRO-α, β-NGF, TNF-α, and M-CSF and altered susceptibility to asthma. These findings highlight the potential immunopathogenic roles of these cytokines in the onset and development of asthma.
- Open Access
- 10 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1636871
Correction: Association of early enoxaparin prophylactic anticoagulation with ICU mortality in critically ill patients with chronic obstructive pulmonary disease: a machine learning-based retrospective cohort study
Enoxaparin prophylactic anticoagulation with ICU mortality in critically ill patients with chronic obstructive pulmonary disease: a machine learning-based retrospective cohort study. Front. Pharmacol. 16:1588846. doi: 10.3389/fphar.2025.1588846 In the published article, there was an error in the correspondence section. Jing Zhang was erroneously designated as a corresponding author instead of Qingyuan Zhan. The correspondence section has been updated.In the published article, there was an error in the author list, and authors Shan Lin and Qingyuan Zhan were erroneously marked as having contributed equally to this work. The corrected author list appears below. Shan Lin1* †, Jing Zhang2 †, Xin Dang1 and Qingyuan Zhan3* † These authors have contributed equally to this workThe authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
- 10 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1636871
Open AccessCorrection: Association of early enoxaparin prophylactic anticoagulation with ICU mortality in critically ill patients with chronic obstructive pulmonary disease: a machine learning-based retrospective cohort study
Enoxaparin prophylactic anticoagulation with ICU mortality in critically ill patients with chronic obstructive pulmonary disease: a machine learning-based retrospective cohort study. Front. Pharmacol. 16:1588846. doi: 10.3389/fphar.2025.1588846 In the published article, there was an error in the correspondence section. Jing Zhang was erroneously designated as a corresponding author instead of Qingyuan Zhan. The correspondence section has been updated.In the published article, there was an error in the author list, and authors Shan Lin and Qingyuan Zhan were erroneously marked as having contributed equally to this work. The corrected author list appears below. Shan Lin1* †, Jing Zhang2 †, Xin Dang1 and Qingyuan Zhan3* † These authors have contributed equally to this workThe authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
- Open Access
- 12 May 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1588846
Association of early enoxaparin prophylactic anticoagulation with ICU mortality in critically ill patients with chronic obstructive pulmonary disease: a machine learning-based retrospective cohort study
Background: Chronic obstructive pulmonary disease (COPD) is a major contributor to global morbidity and mortality, particularly during acute exacerbations that frequently require intensive care unit (ICU) admissions. Considering the hypercoagulability associated with COPD, which intensifies during acute episodes, prophylactic anticoagulation therapy may help reduce ICU mortality. However, this potential has not been explored specifically in this population of patients.Methods: We conducted a retrospective cohort study using data from the Medical Information Mart for Intensive Care IV, spanning patient records from 2008 to 2019 at the Beth Israel Deaconess Medical Center in Boston. This study focused on critically ill patients with COPD, employing feature selection methods, to identify key variables influencing clinical outcomes. The impact of prophylactic enoxaparin on prognosis was assessed using logistic regression models and Kaplan–Meier survival analysis.Results: Our analysis included 4,433 critically ill patients with COPD, of whom 446 received enoxaparin within the first 72 h of ICU admission. The primary analysis showed that patients treated with enoxaparin experienced a 48% lower ICU mortality (odds ratio 0.52 [95% confidence interval 0.31–0.86]) than that of those not treated with enoxaparin, with an E-value of 3.26. This association between enoxaparin use and lower ICU mortality persisted across all subgroups examined. Additionally, a visual analysis of patients with varying Oxford acute severity of illness score (OASIS) indicated that early enoxaparin use was linked to an improved prognosis in critically ill patients with COPD who had higher OASIS than in those without.Conclusion: Early initiation of prophylactic enoxaparin therapy was significantly associated with low ICU mortality in critically ill patients with COPD, especially in high-risk subgroups. These findings support the need for randomized controlled trials to confirm the effectiveness of thromboprophylaxis in this specific patient population and to evaluate the potential bleeding risks.
- 12 May 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1588846
Open AccessAssociation of early enoxaparin prophylactic anticoagulation with ICU mortality in critically ill patients with chronic obstructive pulmonary disease: a machine learning-based retrospective cohort study
Background: Chronic obstructive pulmonary disease (COPD) is a major contributor to global morbidity and mortality, particularly during acute exacerbations that frequently require intensive care unit (ICU) admissions. Considering the hypercoagulability associated with COPD, which intensifies during acute episodes, prophylactic anticoagulation therapy may help reduce ICU mortality. However, this potential has not been explored specifically in this population of patients.Methods: We conducted a retrospective cohort study using data from the Medical Information Mart for Intensive Care IV, spanning patient records from 2008 to 2019 at the Beth Israel Deaconess Medical Center in Boston. This study focused on critically ill patients with COPD, employing feature selection methods, to identify key variables influencing clinical outcomes. The impact of prophylactic enoxaparin on prognosis was assessed using logistic regression models and Kaplan–Meier survival analysis.Results: Our analysis included 4,433 critically ill patients with COPD, of whom 446 received enoxaparin within the first 72 h of ICU admission. The primary analysis showed that patients treated with enoxaparin experienced a 48% lower ICU mortality (odds ratio 0.52 [95% confidence interval 0.31–0.86]) than that of those not treated with enoxaparin, with an E-value of 3.26. This association between enoxaparin use and lower ICU mortality persisted across all subgroups examined. Additionally, a visual analysis of patients with varying Oxford acute severity of illness score (OASIS) indicated that early enoxaparin use was linked to an improved prognosis in critically ill patients with COPD who had higher OASIS than in those without.Conclusion: Early initiation of prophylactic enoxaparin therapy was significantly associated with low ICU mortality in critically ill patients with COPD, especially in high-risk subgroups. These findings support the need for randomized controlled trials to confirm the effectiveness of thromboprophylaxis in this specific patient population and to evaluate the potential bleeding risks.